Table 3.
Hormone use in controls and POP-HQ groups
| CONTROL | POP-A(dipose) | POP-I(nflammatory) | POP-V(ascular) | |
|---|---|---|---|---|
| N | 15 | 8 | 9 | 11 |
| Hormone | ||||
| No hormone use | 9 (60%) | 8 (100%) | 6 (66.7%) | 4 (36.4%) |
| Oral estrogen | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Oral progesterone | 4 (26.6%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Oral contraceptive Pills | 1 (6.7%) | 0 (0%) | 1 (11.1%) | 0 (0%) |
| IUD (progesterone) | 1 (6.7%) | 0 (0%) | 1 (11.1%) | 0 (0%) |
| Vaginal estrogen | 0 (0%) | 0 (0%) | 1 (11.1%) | 7 (63.6%) |
| Other- transdermal estrogen, transdermal progesterone, oral and transdermal testosterone | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
A summary of the hormone replacement therapy for the subjects in these phenotypes is included